Monograph
C09AA08 - Cilazapril |
Propably not porphyrinogenic |
PNP |
Rationale
No evidence of significant CYP-dependent metabolism. Occasional observations of tolerance. Two references stating (probable) non-porphyrinogenicity.
Risk for gastrointestinal adverse event in the form of nausea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Hydrolyzed to cilazaprilate, a long term ACE- inhibitor. Excreted (90%) in unchanged form by the kidneys. Andersson, patient report (n=2): tolerated. South African list: use with care. French list: authorized.
Therapeutic characteristics
A common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Other common side effects are headache and fatigue.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
United Kingdom
Poland
Serbia© NAPOS 2024